---
title: "Antidepressant Side-Effects: Cardiometabolic & Physiological Guide"
description: "How common antidepressants differ on weight, blood pressure, heart rate, cholesterol, glucose, liver enzymes, electrolytes, and QTc — plus monitoring and safer choices by risk profile."
category: "Mental Health"
publishDate: "2025-10-23"
tags: ["antidepressants", "side-effects", "cardiometabolic", "metabolic-health"]
draft: false
---

## Intro
Antidepressants can meaningfully affect **weight**, **blood pressure (BP)**, **heart rate (HR)**, **lipids**, **glucose**, and **liver enzymes**. These effects vary by drug and class, and matter most for people with **obesity, hypertension, diabetes risk, dyslipidemia, or cardiovascular disease**.

Short-term randomized trials show **wide physiological spreads between agents**, even when antidepressant efficacy is similar.

---

## Key Points
- Short-term trials show about **4 kg spread in weight change**, **~20 bpm spread in heart rate**, and **~11 mmHg spread in systolic BP** across antidepressants.
- **SNRIs** (venlafaxine, desvenlafaxine, duloxetine, levomilnacipran): tend to raise **BP** and **cholesterol**; duloxetine also shows small increases in **glucose** and **AST/ALT**.
- **TCAs** (amitriptyline, imipramine, maprotiline): tend to raise **HR**, **BP**, and **weight**.
- **Agomelatine**, **fluoxetine**, and **bupropion**: generally more favorable **short-term weight** profiles.
- QTc prolongation and hyponatremia are uncommon in short RCTs, but real-world risk rises in **older, multimorbid** populations.

---

## Evidence Summary (Network Meta-Analysis)
**Source:** Pillinger et al., *The Lancet* (2025)  
**Data:** 151 RCTs · ~58,500 participants · 30 antidepressants

**Key findings**
- SNRIs increase **BP** and **cholesterol**; duloxetine shows small increases in **glucose** and **liver enzymes**.
- TCAs increase **heart rate**, **blood pressure**, and **weight**.
- Agomelatine, fluoxetine, and bupropion are associated with **less weight gain or modest short-term weight loss**.
- Short-term trials show **minimal QTc and sodium signal**, which may underestimate real-world risk.

---

## Options by Clinical Profile

### Metabolic risk (obesity, type 2 diabetes, dyslipidemia)
**Prefer**
- Agomelatine
- Fluoxetine
- Bupropion

**Avoid when possible**
- Mirtazapine
- TCAs
- High-dose SNRIs

### Hypertension or cardiovascular disease
Avoid or monitor closely:
- Venlafaxine
- Desvenlafaxine
- Duloxetine
- Levomilnacipran
- TCAs

### Weight-gain sensitivity
Higher risk:
- Mirtazapine
- Amitriptyline
- Maprotiline

Lower risk:
- Bupropion
- Fluoxetine
- Agomelatine

### Older adults / polypharmacy
- Start low, titrate slowly.
- Consider baseline and follow-up **sodium** and **QTc** when risk factors exist.

---

## Monitoring (First 8–12 Weeks)
- **Baseline → Week 4 → Week 8:** weight, waist circumference, BP, HR.
- **Labs (if risk present):**
  - Fasting **lipids** and **glucose** (especially with SNRIs or metabolic risk).
  - **Liver enzymes** (especially duloxetine / desvenlafaxine / levomilnacipran or hepatic history).
- **Electrolytes (Na⁺)** and **ECG (QTc)** for older adults or those on diuretics / QT-prolonging drugs.

---

## Generic → Trade Names (Quick Map)

**SSRIs:**  
Fluoxetine (Prozac), Sertraline (Zoloft), Paroxetine (Paxil), Citalopram (Celexa), Escitalopram (Lexapro), Fluvoxamine (Luvox)

**SNRIs:**  
Venlafaxine (Effexor), Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima)

**Atypical:**  
Bupropion (Wellbutrin), Agomelatine (Valdoxan), Mirtazapine (Remeron)

**TCAs:**  
Amitriptyline (Elavil), Nortriptyline (Pamelor), Imipramine (Tofranil), Doxepin (Sinequan), Maprotiline (Ludiomil)

---

## FAQ

**Do SSRIs behave the same physiologically?**  
No. Paroxetine tends to have more lipid/weight effects; fluoxetine, sertraline, and escitalopram are more neutral short-term.

**If weight falls early, will it stay down?**  
Not reliably. Longer observational cohorts often show net weight gain with chronic use.

**Are QTc or sodium problems common?**  
Not in short-term RCTs, but registry data in older or multimorbid patients shows increased risk — monitor when indicated.

---

## Further Reading
- Pillinger T et al. *The Lancet* (2025). doi:10.1016/S0140-6736(25)01293-0  
- NICE. *Depression in adults: treatment and management.*

<script type="application/ld+json">
{JSON.stringify({
  "@context":"https://schema.org",
  "@type":"MedicalWebPage",
  "name":"Antidepressant Side-Effects: Cardiometabolic & Physiological Guide",
  "description":"Comparative cardiometabolic and physiological side-effects of antidepressants with monitoring guidance.",
  "datePublished":"2025-10-23",
  "dateModified":"2025-10-23",
  "breadcrumb":{
    "@type":"BreadcrumbList",
    "itemListElement":[
      {"@type":"ListItem","position":1,"name":"Guides","item":"https://patientguide.io/guides"},
      {"@type":"ListItem","position":2,"name":"Mental Health","item":"https://patientguide.io/guides/category/mental-health"},
      {"@type":"ListItem","position":3,"name":"Antidepressant Side-Effects","item":"https://patientguide.io/guides/antidepressant-side-effects"}
    ]
  }
})}
</script>
